Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: PK who wrote (955)	5/11/1998 4:16:00 PM
From: Phil Cressman	Respond to of 2135

Not so fast! To produce the proteins is going to cost major bucks. The proteins haven't yet indicated any value and won't for a few years. The best you can hope for is a pharma to kick in dollars for R&D for which they will want to buy shares and obtain marketing rights to proteins. What ENMD will hopefully end up with in 4 or 5 years is a cash flow from royalties if the compounds prove out. During this time they also have to foot a share of the R&D costs. Expect another round of financing and shareholder dilution this year or early next.